key: cord-0862616-y17mfrvb
authors: Talon, Laurie; Fourneyron, Virginie; Trapani, Alexandre; Pereira, Bruno; Sinegre, Thomas; Lebreton, Aurélien
title: Analytical performance of a new immunoturbidimetric D‐dimer assay and comparison with available assays
date: 2022-02-06
journal: Res Pract Thromb Haemost
DOI: 10.1002/rth2.12660
sha: 8fd956a73b46a5ba4d4aecececcafd177b319d76
doc_id: 862616
cord_uid: y17mfrvb

BACKGROUND: The routine D‐dimer quantification to exclude venous thromboembolism has led to the development of many assays, the usefulness of which depends on their reliability and performance. OBJECTIVE: We evaluated the analytical performances of the immunoturbidimetric Yumizen G DDi 2 assay (HORIBA Medical, Montpellier, France) performed on the Yumizen G800 analyzer and compared it with other available D‐dimer assays. METHODS: Within‐run and between‐run imprecision were evaluated using low‐ and high‐level quality‐control plasma samples. Interference due to hemolysis, icterus, lipemia, rheumatoid factor (RF), or heterophilic antibodies (human antimouse antibodies [HAMAs]) was evaluated by spiking plasma samples with hemolysate, bilirubin, Intralipid, RF, or HAMAs. The measurements obtained with the different D‐dimer assays were compared using Passing‐Bablok regression analysis and Bland‐Altman plot method, using fresh citrated plasma samples collected from 66 consecutive routine patients with a wide range of D‐dimer concentrations. RESULTS: Within‐ and between‐run variation coefficients for the Yumizen G DDi 2 assay ranged from 1.7% to 5.8% and from 2.8% to 5.5%, respectively. Hemolysis and icterus did not have any effect up to 10 g/L hemoglobin and 300 mg/L bilirubin. Lipemia seemed to generate an underestimation of D‐dimer concentration when the Intralipid concentration was >5 g/L. RF and HAMAs did not have any effect. The Passing‐Bablok and Bland‐Altman analyses showed small differences with other available D‐dimer assays, which were more pronounced with increasing values. CONCLUSIONS: Its analytical performances and main technical features indicate that the new Yumizen G DDi 2 assay is suitable for the rapid quantification of D‐dimer in clinical hemostasis laboratories.

Venous thromboembolism (VTE), which includes deep vein thrombosis and pulmonary embolism, represents a major public health problem, with about 10 million cases worldwide per year that are associated with substantial mortality and morbidity. 1 form a polymer, and the transglutaminase factor XIII, also activated by the thrombin, stabilizes the initial fibrin polymer. Next, plasmin cleaves fibrin into fibrin degradation products, among which are Ddimer. The D-dimer is a metabolite of fibrinolysis that increases as a result of hypercoagulability and hyperfibrinolysis. Therefore, Ddimer measurement is a sensitive but nonspecific indicator that has been widely used by clinicians to exclude VTE. D-dimer assays have also been used to assess the risk of VTE recurrence, 5, 6 to help define the optimal duration of anticoagulant treatment, 7 and to predict the VTE risk in hospitalized patients. 8, 9 Enzyme-linked immunosorbent assays have been considered the reference method for D-dimer measurement for a long time, 10,11 but they are not suitable for routine use due to the significant analytical between-run imprecision, lack of automation, and the time required. 9 An automated enzyme-linked immunofluorescence assay was then developed that provides faster results (Vidas D-dimer Exclusion II assay; bioMérieux, Inc., Durham, NC, USA) and is currently the most clinically validated assay for D-dimer measurement. 3, 12, 13 More recently, chemiluminescent assays and latex-enhanced immunoturbidimetric assays have shown good sensitivity and negative predictive values. 4, 14, 15 These assays allow the measurement of D-dimer concentration simultaneously with other routine coagulation assays on the same analyzer.

Currently, many D-dimer assays are available that differ in terms of the D-dimer epitope targeted by the antibody, capture and detection methods, instrumentation required, calibration standards, and result expression. 9, 16 Due to this heterogeneity, it is recommended to assess the analytical performances of an assay before its implementation in clinical strategies for VTE diagnosis and monitoring.

The objective of this study was to evaluate the analytical performance of the new D-dimer immunoturbidimetric assay (Yumizen G DDi 2; HORIBA Medical, Montpellier, France) designed for the fully automated Yumizen G800 analyzer and to compare it with other available D-dimer assays.

Blood samples from hospitalized patients were collected in tubes containing 0.109 M trisodium citrate (Vacutainer; Becton Dickinson, Franklin Lakes, NJ, USA) with a 21G needle, after discarding the first milliliters of blood. Plasma was obtained by centrifugation at 2250 g at room temperature for 15 minutes, and was analyzed within 4 hours of collection. As the remaining plasma was used for Yumizen G DDi 2 testing, no blood sample was specifically collected for this study. This study was approved by the South-East VI Ethics Committee (France, AU765).

D-dimer concentration was measured using the Yumizen G DDi 2 assay and the Yumizen G800 coagulation analyzer (HORIBA Medical) according to the manufacturer's instructions. This is a fully automated immunoturbidimetric assay for the quantitative deter- (1:4) in the buffer Yumizen G Imidazol. The ready-to-use liquid format minimizes the preparation time, and the reagent is precalibrated, removing the need of a costly and time-consuming calibration step.

Precision was evaluated using manufactured human plasma-based quality controls at low and high concentration (Yumizen G CTRL DDi I and II). Within-run imprecision was assessed in 30 sequential runs and between-run imprecision by measuring the same controls in 15 different series twice per day, by using an identical lot of reagents. The final results were reported as a coefficient of variation (CV).

2.3.2 | Limit of blank, limit of detection, and limit of quantification These parameters were assessed according to the Clinical and Laboratory Standards Institute (CLSI) EP17-A2 standard. 17 The LoB, defined as the highest measurement result that can be reliably measured in a blank sample, was estimated by measuring 30 replicates of a sample without D-dimer molecules, and calculated with the following formula: LoB = mean blank + 1.645 SD blank . The dilution buffer (Yumizen G Imidazol) was the blank.

The LoD, defined as the lowest D-dimer concentration likely to be reliably detected by the assay was obtained from 10 measurements in a single run of a plasma sample with a D-dimer concentration of ≈2×LoB, and was determined with the following formula:

The LoQ, defined as the smallest value with an acceptable level of confidence and known uncertainty, was estimated by measuring 11 samples with mean D-dimer concentrations from 33 to 333 ng/ mL FEU (10 repeated measurements), and a nonlinear relationship calculated between the measurement error (CV%, y axis) and the Ddimer concentration (ng/mL FEU, x axis). 

Interference by hemolysis, icterus, and lipemia (HIL) was evaluated to determine their impact on the D-dimer results. HIL interferences were assessed by adding known increasing concentrations of hemoglobin, bilirubin, and Intralipid 20% to 10 different samples with different D-dimer levels (including 5 samples with values around the threshold value).

Hemoglobin was obtained by freezing washed and centrifuged erythrocytes. The supernatant was collected to create a hemolysate that was then spiked in the D-dimer-positive plasma samples. 18, 19 A control sample with only the diluent (Yumizen G Imidazol), to account for dilution, was also used. A range of hemoglobin concentrations was prepared to obtain samples with 0, 3, 5, 7, and 10 g/L of hemoglobin, according to the measurement obtained on an XN-10 analyzer (Sysmex Corporation, Kobe, Japan). The interference was evaluated by calculating the bias percentage with the following for- sample with diluent alone (Yumizen G Imidazol), to account for dilution, was also used. Results were calculated as the mean difference (percentage) relative to the control value (sample before spiking).

Comparison studies were carried out using fresh citrated plasma 

Statistical analyses were performed with Prism software ver- 

The within-run and between-run imprecision results of the Yumizen G DDi 2 assay are summarized in Table 1 . The within-run imprecision ranged between 1.7% for the high control sample (mean value, 1044 ng/mL FEU) and 5.8% for the low control sample (mean value, 330 ng/mL FEU, close to the threshold value). The betweenrun imprecision was assessed with another quality control batch and ranged between 2.8% (mean value, 2015 ng/mL FEU) and 5.5%

(mean value, 500 ng/mL FEU).

Using the CLSI approach, the LoB and LoD were 52 ng/mL FEU and 64 ng/mL FEU, respectively. The LoQ at 10% CV was estimated at 112 ng/mL FEU (Figure 1 ). The assay linearity was excellent up to 32 700 ng/mL FEU, as attested by the linear regression analysis (y = −0.9754x − 173.8) and the coefficient of correlation (r = .998; P < .0001) (Figure 2 ). Figure 5F ).

When only values <1000 ng/mL were considered, the Passing-Bablok regression analysis showed also proportional difference between these two assays with y = 11.9 + 0.7x (intercept 95% CI, −72. 

D-dimer measurement is one of the most commonly requested tests in the hemostasis laboratory, mainly to exclude thromboembolism.

Recently, various immunoturbidimetric D-dimer assays have been marketed for routine laboratory practice. Most of these assays are fully automated and allow D-dimer measurement simultaneously with other routine coagulation assays, which is convenient for daily use. However, due to differences in the technologies on which these assays are based, the analytical performance of each new assay needs to be evaluated before implementation.

This study describes the analytical performance of the Yumizen Clinically significant interferences due to hemolysis, icterus, and lipemia are a common issue in immunoassays. [23] [24] [25] In this study, no significant impact of hemolysis was found up to hemoglobin concentrations of 10 g/L, which was higher compared with the manufacturers' data ( Table 2) HemosIL D-dimer HS 500 assay and the ACL TOP 550 analyzer). 28 Conversely, no interference was observed below 10 g/L of Intralipid for the plasma samples with higher D-dimer concentrations.

The occurrence of interfering heterophilic antibodies (eg, HAMAs and RF) with antibody of D-dimer assays has been reported in the literature and is responsible for false-negative or false-positive results with meaningful clinical implications. [29] [30] [31] [32] No interference of HAMAs (up to 500 ng/mL) and RF (up to 935 UI/mL) was detected, supporting the safety of the D-dimer results obtained with the Yumizen G DDi 2 reagent, RF levels rarely exceeding 1000 UI/mL in clinical practice. 33 There are few data in the literature concerning HAMA concentrations in clinical practice, plasma samples being usually treated with a specific heterophilic blocking reagent when HAMA interference was suspected, instead of measuring HAMA concentration. [30] [31] [32] 34 Good correlation was observed between Yumizen G DDi 2 and all the other immunoassays tested in this study, with correlation co- Our results are in line with the previously published statement that the major drawback of D-dimer assays is the high variability observed between commercial immunoassays. This persisting variability might be explained by the heterogeneity in antibody specificity (preference for high-or low-molecular-weight fibrin degradation products) or complexity of the targeted analyte, and by the lack of international certified internal controls or calibrators. 9, 35, 36 This study presents some limitations. Different approaches exist to test HIL interferences. Spiking plasmas with hemolysate, lipemic, or icteric preparations may fail to show the same effects as naturally In conclusion, our study found that the analytical performances of the Yumizen G DDi 2 assay are satisfactory. The automated

Yumizen G800 rapidity and random access testing are additional advantages of this method for routine use in clinical hemostasis laboratories. 

Thrombosis: a major contributor to global disease burden

Plasma measurement of D-dimer as diagnostic aid in suspected venous thromboembolism: an overview

Exclusion of deep venous thrombosis with D-dimer testing-comparison of 13 D-dimer methods in 99 outpatients suspected of deep venous thrombosis using venography as reference standard

Diagnostic accuracy of D-dimer test for exclusion of venous thromboembolism: a systematic review

D-dimer at venous thrombosis diagnosis is associated with risk of recurrence

D-dimer levels and risk of recurrence following provoked venous thromboembolism: findings from the RIETE registry

Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study

The IMPROVEDD VTE risk score: incorporation of D-dimer into the IMPROVE score to improve venous thromboembolism risk stratification

D-dimer: preanalytical, analytical, postanalytical variables, and clinical applications

Review of D-dimer testing: good, bad, and ugly

Widely used types and clinical applications of D-dimer assay

VIDAS D-dimer: fast quantitative ELISA for measuring D-dimer in plasma

The VIDAS D-dimer test for venous thromboembolism: a prospective surveillance study shows maintenance of sensitivity and specificity when used in normal clinical practice

Performance of the automated and rapid STA Liatest D-dimer on the STA-R analyzer

Analytical performances of the D-dimer assay for the Immulite 2000 automated immunoassay analyser

D-dimer antigen: current concepts and future prospects

Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures

An approach to analytical validation and testing of body fluid assays for the automated clinical laboratory

Hemolysis, Icterus, and Lipemia/Turbidity Indices as Indicators of Interference in Clinical Laboratory Analysis

Effects of hemolysis, bilirubin, and lipemia interference on coagulation tests detected by two analytical systems

Current databases on biological variation: pros, cons and progress

Desirable specifications for total error, imprecision, and bias, derived from intra-and inter-individual biologic variation

Hemolyzed specimens: a reason for rejection or a clinical challenge?

Survey on the prevalence of hemolytic specimens in an academic hospital according to collection facility: opportunities for quality improvement

Prevalence and type of pre-analytical problems for inpatients samples in coagulation laboratory

Hemolysis interference in 10 coagulation assays on an instrument with viscositybased, chromogenic, and turbidimetric clot detection

Interference of icterus on plasma D-dimer levels measured using immunoturbidimetric assays

Estimation of lipemia interference with automated HIL-test on D-dimer ACL TOP 50 series analysis -reveals a higher cut-off than manufacturer's recommendations

False-positive Ddimer result in a latex-enhanced immunoassay caused by interfering human anti-mouse antibodies

Incohérence entre deux méthodes de dosage des Ddimères : un cas d'interférence d'anticorps humain anti-souris

Interference from heterophilic antibodies in D-dimer assessment. A case report

What makes D-dimer assays suspicious-heterophilic antibodies?

Elevated rheumatoid factor and long term risk of rheumatoid arthritis: a prospective cohort study

Clinical laboratory investigation of a patient with an extremely high D-dimer level: a case report

ISTH interim guidance on recognition and management of coagulopathy in COVID-19

Is it possible to make a common reference standard for D-dimer measurements? Communication from the ISTH SSC Subcommittee on Fibrinolysis

Analytical performance of a new immunoturbidimetric D-dimer assay and comparison with available assays